Genfit rises after liver disease treatment meets late-stage study goal

Genfit SA

30/06/2023 13:27

** U.S.-listed shares of French biopharma co Genfit SA
 GNFT.PA   GNFT.O  rise 1.98% premarket to $4.75
    ** Co and partner Ipsen SA  IPN.PA  say elafibranor, its
treatment for a rare cholestatic liver disease, met its goal in
a late-stage study
    ** In the trial, 51% of patients on elafibranor 80mg
achieved a cholestasis response, compared with 4% on placebo
    ** Ipsen intends to submit regulatory applications for
elafibranor following discussions with the U.S. FDA and the
European Medicines Agency
    ** Elafibranor is being studied as a treatment for patients
with primary biliary cholangitis (PBC), who have an inadequate
response or intolerance to ursodeoxycholic acid, the current
standard of care therapy 
    ** PBC is a chronic disease in which the small bile ducts in
the liver become injured and inflamed and are eventually
destroyed
    ** Up to last close, GNFT's U.S.-listed stock down ~7% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))